TG Therapeutics, Inc. to Participate in Upcoming Investment Conferences in September

NEW YORK, Sept. 8, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced its participation at two upcoming investment conferences this month. Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference, being held at the St. Regis Hotel in New York City, tomorrow September 9, 2015 at 3:00pm ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at

On Thursday, September 10, 2015 at 8:15am ET, Mr. Weiss will participate in a panel discussion at the Wells Fargo Securities 2015 Healthcare Conference being held at the Hyatt Regency in Boston, MA. This event will not be webcast.


TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, as well as an antibody research program to develop anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.


CONTACT: Jenna Bosco Director- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email:

Source:TG Therapeutics, Inc.